Adjuvant radioactive iodine therapy is associated with improved survival for patients with intermediate-risk papillary thyroid cancer.
Top Cited Papers
Open Access
- 1 April 2015
- journal article
- Published by The Endocrine Society in Journal of Clinical Endocrinology & Metabolism
- Vol. 100 (4), 1529-36
- https://doi.org/10.1210/jc.2014-4332
Abstract
Papillary thyroid cancer (PTC) is the most common endocrine malignancy. The long-term prognosis is generally excellent. Due to a paucity of data, debate exists regarding the benefit of adjuvant radioactive iodine therapy (RAI) for intermediate-risk patients. The objective of the study was to examine the impact of RAI on overall survival in intermediate-risk PTC patients. Adult patients with intermediate-risk PTC who underwent total thyroidectomy with/without RAI in the National Cancer Database, 1998-2006, participated in the study. Intermediate-risk patients, as defined by American Thyroid Association risk and American Joint Commission on Cancer disease stage T3, N0, M0 or Mx, and T1-3, N1, M0, or Mx were included in the study. Patients with aggressive variants and multiple primaries were excluded. Overall survival (OS) for patients treated with and without RAI using univariate and multivariate regression analyses was measured. A total of 21 870 patients were included; 15 418 (70.5%) received RAI and 6452 (29.5%) did not. Mean follow-up was 6 years, with the longest follow-up of 14 years. In an unadjusted analysis, RAI was associated with improved OS in all patients (P < .001) as well as in a subgroup analysis among patients younger than 45 years (n = 12 612, P = .002) and 65 years old and older (median OS 140 vs 128 mo, n = 2122, P = .008). After a multivariate adjustment for demographic and clinical factors, RAI was associated with a 29% reduction in the risk of death, with a hazard risk 0.71 (95% confidence interval 0.62-0.82, P < .001). For age younger than 45 years, RAI was associated with a 36% reduction in risk of death, with a hazard risk 0.64 (95% confidence interval 0.45- 0.92, P = .016). This is the first nationally representative study of intermediate-risk PTC patients and RAI therapy demonstrating an association of RAI with improved overall survival. We recommend that this patient group should be considered for RAI therapy.Keywords
This publication has 19 references indexed in Scilit:
- Streamlining variability in hospital charges for standard thyroidectomy: Developing a strategy to decrease wasteSurgery, 2014
- Selective Use of Radioactive Iodine in Intermediate-Risk Papillary Thyroid CancerJAMA Otolaryngology–Head & Neck Surgery, 2012
- Rising incidence of second cancers in patients with low‐risk (T1N0) thyroid cancer who receive radioactive iodine therapyCancer, 2011
- Late side effects of radioactive iodine on salivary gland function in patients with thyroid cancerHead & Neck, 2010
- Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid CancerThyroid®, 2009
- Using the NCDB for cancer care improvement: An introduction to available quality assessment toolsJournal of Surgical Oncology, 2009
- The National Cancer Data Base: A Powerful Initiative to Improve Cancer Care in the United StatesAnnals of Surgical Oncology, 2008
- Local and regional control in patients with papillary thyroid carcinoma: specific indications of external radiotherapy and radioactive iodine according to T and N categories in AJCC 6th editionEndocrine-Related Cancer, 2006
- Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancerAmerican Journal Of Medicine, 1994
- Clinical utility of posttreatment radioiodine scans in the management of patients with thyroid carcinoma.Journal of Clinical Endocrinology & Metabolism, 1994